SCHEMBL16398461

SCHEMBL16398461

CCc1nc(-c2ccc(Cl)cc2)sc1C=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
TRPM8 Q7Z2W7 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
GAA P10253 1/20 0.42
PTPN11 Q06124 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
SLC22A1 O15245 1/20 0.40
DHFR P00374 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
HEXA P06865 1/20 0.40
HEXB P07686 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19936638 0.84 AGER (0.43) MAPTTRPM8SMN1; SMN2RAB9AKDM4E
SCHEMBL2070188 0.80 SMN1; SMN2 (0.56) MAPTTRPM8SMN1; SMN2RAB9AKDM4E
SCHEMBL624460 0.79 MAPT (0.44) MAPTSMN1; SMN2RAB9AKDM4ENPC1
SCHEMBL28290873 0.78 HRH3 (0.49) MAPTTRPM8SMN1; SMN2RAB9AKDM4E
SCHEMBL21376152 0.76 ALDH1A1 (0.44) MAPTTRPM8SMN1; SMN2RAB9AKDM4E
SCHEMBL16399629 0.76 HRH3 (0.45) MAPTTRPM8SMN1; SMN2RAB9AKDM4E
SCHEMBL12344791 0.75 RAB9A (0.67) MAPTTRPM8SMN1; SMN2RAB9AKDM4E
SCHEMBL18003327 0.73 ALDH1A1 (0.41) MAPTSMN1; SMN2RAB9AKDM4ENPC1
SCHEMBL13139990 0.72 F11 (0.40) MAPTKDM4ENPC1KMT2ALMNA
SCHEMBL30638210 0.72 MEN1 (0.33) MAPTRAB9ANPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 MAPT 2196/4885TRPM8 3537/4885SMN1; SMN2 3834/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 MAPT 2196/4885TRPM8 3537/4885SMN1; SMN2 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.